An observational study in Hypercholesterolemia, sponsored by AstraZeneca. Completed at 10 sites in Turkey. Per ClinicalTrials.gov, last updated 2014-01-09.
Sponsored by AstraZeneca · Observational
In Turkey statin compliance is lower than EU countries. (EURIKA). We will assess the underlying causes of statin incompliance. The investigators will build patient and physician education programs to improve compliance in TURKEY. Our aim is to assess patients' and physicians' attitudes to statins by mean of HABIT Patient and Physician survey respectively.
Observational study to understand patients' and physicians' attitudes to Statins in TurkeY
1,238 studies on the registry are indexed under Hypercholesterolemia; 109 are open to participants now.
This study's enrollment of 500 is below the median of 800 across 185 observational studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients > 18 years of age, diagnosed with hypercholesterolemia and prescribed with at least one statin irrespective of its type and/or dose. The inclusion period will last 6 months, on which consecutive patients attending the outpatient Family Physicians or Cardiologists office will be invited to participate.
Exclusion Criteria:
HABIT scores for the patients of the following questionnaire items (see description)
* Total score * Effectiveness of cholesterol-lowering medications * Association of high doses with adverse experiences * Risk of high cholesterol * Severity of high cholesterol * Frustration with the process of care * Difficulty in following advice / making changes * Doctor-patient communication * Communication about cholesterol
Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
HABIT scores for the physicians of the following questionnaire items (see description)
* Total score * Effectiveness of statins * Patients view titration negatively * Risk associated with higher doses * Close enough to goal * Urgency of getting to goal * Utility of diet and exercise * Time and resources to counsel patients * Physician self-efficacy in treating patients to goal
Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
Socio-demographics terms
* Age * Sex * Smoking habits * Educational level * Professional status * Place of residence * Income level * Healthcare insurance level
Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
Clinical characteristics
* Date of diagnosis * Current disease status: Physical examination results (vital signs and anthropometric measurements) * Cardiovascular risk factors * Relevant co-morbidities * Cholesterol levels (LDL-C) at inclusion (if available) * Number of hospitalizations during the last 12 months * Duration of statin use in the past year
Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
Clinical characteristics (continuation)
* List of poor compliance (discontinuation) causes in the past one year * Treatment discontinuation (statins), reported causes * Time to discontinuation of statin therapy (in early stage/medium term/long term) * Change in lipid levels and other laboratory findings (i.e. hepatic and muscle enzymes) during statin use (before, during and after discontinuation of statin therapy) * List of alternative drug and non-drug therapies received after discontinuation of statin and number (%) of patients who switched to those alternative therapies * Concomitant treatments
Time frame: Participants will be questioned at visit one, visits will take part during 25 weeks of expected study period
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca